The Aim of the Study is to Check Whether Follicular Fluid Evaluation Using a Spectrophotometer Can Differentiate High Quality Oocytes From Low Quality Oocytes. Oocyte Quality Will be Defined Using GDF9, BMP15 and Oocyte Morphology.
Oocyte quality assessment using spectrophotometer: On the OPU (ovum pick-up) day the following blood biochemical markers will be measured as well- Blood interleukins 1-6, cytokine, hormone profile, lipid profile, cortisol.
After collecting the oocytes- the Follicular fluid will be sent for the following tests-
1. mid-infrared spectrometry,
2. P, E2, testosterone, cortisol, cytokines, IL 1-6, lipids, fatty acids.
3. BMP-15, GDF-9 and HSPG2
4. GCMS-Gas Chromatography Mass Spectrophotometer
Study summary
The aim of the study is to check whether follicular fluid evaluation using a spectrophotometer can differentiate high quality oocytes from low quality oocytes. Oocyte quality will be defined using GDF9, BMP15 and oocyte morphology. The correlation between cortisol levels in women and oocyte quality parameters will be estimated.
Eligibility
Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Women aged 20-40 years.
* Undergoing IVF or IVF-ICSI treatment.
* At least five follicles visualized on ultrasound at the time of oocyte retrieval
* Ability to provide written informed consent.
Exclusion Criteria:
* Age \>40 years.
* Fewer than five follicles at the time of oocyte retrieval.
* Use of donor oocytes.
* Significant medical comorbidities affecting ovarian function.
* Known ovarian malignancy or prior ovarian surgery significantly affecting follicular integrity.
Primary outcome measure(s)
Difference in follicular fluid infrared spectrophotometric profiles between high-quality and low-quality oocytes. — 3 Years Infrared spectrophotometric measurements of follicular fluid collected at oocyte retrieval will be obtained using attenuated total reflection Fourier-transform infrared spectroscopy (ATR-FTIR). Oocytes will be classified as high-quality or low-quality based on predefined morphological criteria and follicular fluid levels of GDF9 and BMP15 measured by ELISA. The primary outcome will be reported as differences in normalized spectral absorbance features between the two oocyte quality groups, including discrimination performance using multivariate analysis.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
